MedTrace Logo

Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma

NCT06960863 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-05-07

No results posted yet for this study

Summary

The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients.

Researchers will predict the response to 6 months of HCC immunotherapy regarding improvement of the degree of liver fibrosis, development of liver decompensation, complications, survival, and mortality.

Participants will undergo history-taking, clinical examination, laboratory investigations, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, Triphasic CT abdomen with contrast or MRI (for evaluation of tumor site, size and number), and Fibroscan examination at baseline and follow-up after 6 months.

Conditions

  • Hepato Cellular Carcinoma (HCC)

Interventions

RADIATION

fibroscan

Liver fibrosis and steatosis can be staged using Dimensional ultrasound TE (transient elastography).

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Nabila A Elgazzar, MD · Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-26
Primary Completion
2026-01-15
Completion
2026-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06960863 on ClinicalTrials.gov